Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress.
NETs
Neutrophil extracellular traps
cancer
cardiac
hypertrophy
inflammation
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Cancer is associated with systemic pathologies that contribute to mortality, such as thrombosis and distant organ failure. The aim of this study was to investigate the potential role of neutrophil extracellular traps (NETs) in myocardial inflammation and tissue damage in treatment-naïve individuals with cancer. Mice with mammary carcinoma (MMTV-PyMT) had increased plasma levels of NETs measured as H3Cit-DNA complexes, paralleled with elevated coagulation, compared to healthy littermates. MMTV-PyMT mice displayed upregulation of pro-inflammatory markers in the heart, myocardial hypertrophy and elevated cardiac disease biomarkers in the blood, but not echocardiographic heart failure. Moreover, increased endothelial proliferation was observed in hearts from tumor-bearing mice. Removal of NETs by DNase I treatment suppressed the myocardial inflammation, expression of cardiac disease biomarkers and endothelial proliferation. Compared to a healthy control group, treatment-naïve cancer patients with different malignant disorders had increased NET formation, which correlated to plasma levels of the inflammatory marker CRP and the cardiac disease biomarkers NT-proBNP and sTNFR1, in agreement with the mouse data. Altogether, our data indicate that NETs contribute to inflammation and myocardial stress during malignancy. These findings suggest NETs as potential therapeutic targets to prevent cardiac inflammation and dysfunction in cancer patients.
Identifiants
pubmed: 35309730
doi: 10.1080/2162402X.2022.2049487
pii: 2049487
pmc: PMC8928831
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2049487Informations de copyright
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the author(s).
Références
Dis Chest. 1968 Nov;54(5):403-9
pubmed: 5698585
Lancet Oncol. 2002 Jan;3(1):27-34
pubmed: 11908507
PLoS One. 2018 Jan 11;13(1):e0191231
pubmed: 29324871
Cardiovasc Res. 1996 Jan;31(1):7-18
pubmed: 8849584
Breast Cancer Res. 2006;8(4):212
pubmed: 16887003
Am J Hypertens. 2009 Jul;22(7):763-9
pubmed: 19390513
Eur Heart J. 2015 Jun 7;36(22):1405-14
pubmed: 25660055
N Engl J Med. 2008 May 15;358(20):2107-16
pubmed: 18480203
Cancer Res. 2019 Apr 1;79(7):1274-1284
pubmed: 30894374
Cancer Res. 2016 Aug 1;76(15):4311-5
pubmed: 27402078
Biophys Rev. 2018 Aug;10(4):961-971
pubmed: 29876873
Lupus. 1999;8(1):68-76
pubmed: 10025601
Haematologica. 2020 Jan;105(1):218-225
pubmed: 31048354
Thromb Res. 2018 Apr;164 Suppl 1:S148-S152
pubmed: 29703474
Neurology. 2020 Jun 2;94(22):e2346-e2360
pubmed: 32434865
Thromb Res. 2016 Mar;139:56-64
pubmed: 26916297
HPB (Oxford). 2021 Feb;23(2):309-320
pubmed: 32811764
Nat Rev Immunol. 2013 Jan;13(1):34-45
pubmed: 23222502
Nat Rev Drug Discov. 2019 May;18(5):358-378
pubmed: 30710128
J Thromb Haemost. 2015 Jul;13(7):1310-9
pubmed: 25955268
Eur Heart J. 2014 Apr;35(14):932-41
pubmed: 23990596
Blood. 2014 Jan 2;123(1):141-8
pubmed: 24200682
Science. 2017 Dec 1;358(6367):1202-1206
pubmed: 29191910
Br J Cancer. 2010 Dec 7;103(12):1815-21
pubmed: 21063408
PLoS One. 2012;7(2):e32366
pubmed: 22389696
Biophys J. 2015 Feb 3;108(3):498-507
pubmed: 25650918
Circ Res. 2006 Feb 17;98(3):342-50
pubmed: 16397142
Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):E12245-E12254
pubmed: 30530645
Circ Res. 2020 Apr 24;126(9):1228-1241
pubmed: 32324499
Heart. 2015 Dec;101(23):1874-80
pubmed: 26416836
J Exp Med. 2012 Apr 9;209(4):819-35
pubmed: 22451716
Blood. 2007 Sep 15;110(6):1723-9
pubmed: 17496204
Cancer Res. 2015 Jul 1;75(13):2653-62
pubmed: 26071254
Cancer Res. 2015 Oct 15;75(20):4260-4
pubmed: 26392072
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
J Autoimmun. 2019 Jun;100:120-130
pubmed: 30930069
Nat Med. 2017 Mar 7;23(3):279-287
pubmed: 28267716
Am J Pathol. 2003 Nov;163(5):2113-26
pubmed: 14578209
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):13076-81
pubmed: 22826226
PLoS One. 2011;6(5):e20424
pubmed: 21637823
Circulation. 2017 May 30;135(22):e1054-e1091
pubmed: 28446515
FEBS Lett. 2010 Jul 16;584(14):3193-7
pubmed: 20541553
Front Oncol. 2021 Jan 28;10:619622
pubmed: 33585246
Semin Nephrol. 2010 Nov;30(6):548-56
pubmed: 21146120
Eur Heart J. 2006 Aug;27(15):1847-54
pubmed: 16774985
Clin Chem. 2017 Jan;63(1):325-333
pubmed: 27811204
Cancers (Basel). 2018 Oct 11;10(10):
pubmed: 30314362
Cardiovasc Res. 2021 Oct 14;:
pubmed: 34648022
Sci Rep. 2021 Mar 3;11(1):5074
pubmed: 33658563
Curr Cardiol Rep. 2018 Sep 26;20(11):117
pubmed: 30259192
Br J Haematol. 2019 Jul;186(2):311-320
pubmed: 30968400
Mol Cell Biol. 1992 Mar;12(3):954-61
pubmed: 1312220
J Thromb Haemost. 2018 Mar;16(3):508-518
pubmed: 29325226
Arterioscler Thromb Vasc Biol. 2019 Sep;39(9):1724-1738
pubmed: 31315434
Cancer. 2007 Sep 15;110(6):1376-84
pubmed: 17634949
Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):2032-2040
pubmed: 23818485
Front Immunol. 2019 Jul 31;10:1805
pubmed: 31417569
Int J Mol Sci. 2021 Aug 18;22(16):
pubmed: 34445593
J Clin Invest. 2022 Feb 1;132(3):
pubmed: 34793333
J Investig Med High Impact Case Rep. 2014 Jun 24;2(2):2324709614539283
pubmed: 26425612
J R Soc Med. 1995;88 Suppl 25:24-9
pubmed: 7776324
Crit Rev Oncol Hematol. 2017 Oct;118:79-83
pubmed: 28917273
Oncoimmunology. 2017 Apr 20;6(8):e1320009
pubmed: 28919990